Literature DB >> 21271253

[Acute loss of vision during therapy of chronic hepatitis C].

J P Salgado1, R Khoramnia, M M Maier, C P Lohmann, C Winkler von Mohrenfels.   

Abstract

A patient undergoing combined therapy of chronic hepatitis C with pegylated interferon-α-2a (PEG-IFN-α-2a) and ribavirin suddenly developed severe loss of visual acuity. A central vein occlusion with macular edema was found and intravitreal injections of bevacizumab were initiated. Retinal occlusion is a known complication of therapy with pegylated interferon-α-2a and ribavirin. An interdisciplinary assessment of patients treated for a chronic hepatitis C as well as an early anti-VEGF administration can be helpful in the therapy of this complication of chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21271253     DOI: 10.1007/s00347-010-2327-0

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  9 in total

1.  Interferon-associated combined branch retinal artery and central retinal vein obstruction.

Authors:  Juan E Rubio; Steve Charles
Journal:  Retina       Date:  2003-08       Impact factor: 4.256

2.  Retinal vein thrombosis associated with pegylated-interferon and ribavirin combination therapy for chronic hepatitis C.

Authors:  Iman Zandieh; Mohamed Adenwalla; Cindy Cheong-Lee; Patrick E Ma; Eric M Yoshida
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

3.  Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.

Authors:  Ei Tae Kim; Lee Hoo Kim; Jung Il Lee; Hee Seung Chin
Journal:  Jpn J Ophthalmol       Date:  2009-12-18       Impact factor: 2.447

Review 4.  Retinal vein thrombosis associated with chronic hepatitis C: a case series and review of the literature.

Authors:  A Nadir; A Amin; N Chalisa; D H van Thiel
Journal:  J Viral Hepat       Date:  2000-11       Impact factor: 3.728

Review 5.  Global epidemiology of hepatitis C virus infection.

Authors:  Colin W Shepard; Lyn Finelli; Miriam J Alter
Journal:  Lancet Infect Dis       Date:  2005-09       Impact factor: 25.071

Review 6.  Hepatitis B and hepatitis C in 2009.

Authors:  Patrick Marcellin
Journal:  Liver Int       Date:  2009-01       Impact factor: 5.828

7.  Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion.

Authors:  Ninel Z Gregori; Jaime Gaitan; Philip J Rosenfeld; Carmen A Puliafito; William Feuer; Harry W Flynn; Audina M Berrocal; Luma Al-Attar; Sander Dubovy; William E Smiddy; Stephen G Schwartz; Wen-Hsiang Lee; Timothy G Murray
Journal:  Retina       Date:  2008-10       Impact factor: 4.256

8.  Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C.

Authors:  Damien Sene; Valerie Touitou; Bahram Bodaghi; David Saadoun; Gabriel Perlemuter; Nathalie Cassoux; Jean-Charles Piette; Phuc-Le Hoang; Patrice Cacoub
Journal:  World J Gastroenterol       Date:  2007-06-14       Impact factor: 5.742

9.  Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial.

Authors:  Siegfried G Priglinger; Armin H Wolf; Thomas C Kreutzer; Daniel Kook; Anja Hofer; Rupert W Strauss; Claudia S Alge; Christian Kunze; Christos Haritoglou; Anselm Kampik
Journal:  Retina       Date:  2007-10       Impact factor: 4.256

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.